Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Efficacy of Subcutaneous Enoxaparin Once Daily in the Treatment of Acute Venous Thromboembolic Disease: an Open-Labelled, Non-Comparative, Multicentric, Phase IV Trial.

Trial Profile

The Efficacy of Subcutaneous Enoxaparin Once Daily in the Treatment of Acute Venous Thromboembolic Disease: an Open-Labelled, Non-Comparative, Multicentric, Phase IV Trial.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2010

At a glance

  • Drugs Enoxaparin sodium (Primary)
  • Indications Thromboembolism
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 12 May 2009 Actual patient number (251) added as reported by ClinicalTrials.gov.
    • 27 Feb 2009 Planned number of patients changed from 250 to 251 as reported by ClinicalTrials.gov.
    • 27 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top